H.R. 4132 · 112th Congress
FAST Act
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 112th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
R
StearnsSponsor21 cosponsors · 9 D, 12 R
D
Towns
BB
R
Bilbray
BP
D
Pascrell
MB
R
Burgess
AE
D
Eshoo
BF
D
Filner
PR
R
Roskam
IR
R
Ros-Lehtinen
BG
R
Guthrie
CP
D
Peterson
JP
D
Polis
BP
R
Posey
DR
R
Ross
BD
R
Dold
JH
R
Heck
TD
D
Deutch
AH
D
Hastings
TP
R
Platts
RP
R
Paul
LB
R
Barletta
KH
D
Hochul1 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
Faster Access to Specialized Treatments Act or FAST Act - Expresses the sense of Congress that the Food and Drug Administration (FDA) should apply specified accelerated approval and the fast track provisions to expedite the development and availability of treatments for serious or life-threatening diseases or conditions while maintaining appropriate safety…
What it does: CRS summary · Introduced in House · Mar 5, 2012
Faster Access to Specialized Treatments Act or FAST Act - Expresses the sense of Congress that the Food and Drug Administration (FDA) should apply specified accelerated approval and the fast track provisions to expedite the development and availability of treatments for serious or life-threatening diseases or conditions while maintaining appropriate safety and effectiveness standards.
Amends the Federal Food, Drug, and Cosmetic Act to direct the Secretary of Health and Human Services (HHS), at the request of the sponsor of a new drug, to include as a fast track product a new drug, either alone or in combination with one or more other drugs, that is intended for the treatment of a serious or life-threatening disease or condition.
Permits the Secretary to approve an application for approval of a product for a serious or life-threatening disease or condition, including a fast track product, upon a determination that the product has an effect on: (1) a surrogate endpoint that is reasonably likely to predict clinical benefit; or (2) on a clinical endpoint, including an endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit.
Directs the Secretary, in conjunction with other planned reviews of the new drug review process, to contract with an independent entity with expertise in assessing biopharmaceutical development and regulatory review programs to evaluate the FDA's application of the fast track processes on the development and availability of innovative treatments for patients suffering from serious or life-threatening conditions.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: FAST Act
Also known as: Faster Access to Specialized Treatments Act
Latest action (Mar 9, 2012): Referred to the Subcommittee on Health.
Policy area: Health · Origin: House · Introduced: Mar 5, 2012
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.